J
Janet E. Pope
Researcher at University of Western Ontario
Publications - 593
Citations - 30332
Janet E. Pope is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Rheumatoid arthritis & Population. The author has an hindex of 72, co-authored 557 publications receiving 25112 citations. Previous affiliations of Janet E. Pope include McGill University Health Centre & Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
Arthritis risk after acute bacterial gastroenteritis
TL;DR: Acute bacterial gastroenteritis necessitating medical attention was associated with a higher risk of arthritic symptoms, but notArthritis, up to 4 yrs afterwards, and the nature and chronicity of these arthritis symptoms requires further study.
Journal Article
Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
TL;DR: Canadian rheumatologists are fairly similar in their use of common DMARD and combination therapies in RA, however, regional variability in the use of IM gold and newer DMARD--they were most prescribed in Western Canada and least in Quebec.
Journal Article
Patients with scleroderma may have increased risk of osteoporosis. A comparison to rheumatoid arthritis and noninflammatory musculoskeletal conditions.
TL;DR: The prevalence of OP in patients with SSc was comparable to those with RA, but higher than in the MSK group, and age was found to be an important factor, as expected.
Journal ArticleDOI
Differences in Autoantibody Profiles and Disease Activity and Damage Scores Between Childhood- and Adult-Onset Systemic Lupus Erythematosus: A Meta-Analysis
TL;DR: It is suggested that cSLE may have different autoantibody profiles (increased anti-dsDNA and anticardiolipin antibody, less rheumatoid factor), and more disease activity than adult-onset SLE.
Journal ArticleDOI
The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
Janet E. Pope,Boulos Haraoui,J. Carter Thorne,Andrew Vieira,Melanie Poulin-Costello,Edward C. Keystone +5 more
TL;DR: Withdrawing MTX after 6 months of continuation ETN+MTX in MTX-inadequate responders with active rheumatoid arthritis did not yield the same degree of improvement between 6 and 12’months compared with continuing ETN +MTX, and non-inferiority was not achieved.